TheraRadar
Clinical-Stage Companies / Savara

Savara

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 10/22/2025

10
Total Trials
4
Phase 3
4
Phase 2
2
Recruiting
98
Score

Pipeline by Phase

Phase 3
4
Phase 2
4
Phase 1
2

Therapeutic Focus

Autoimmune Pulmonary Alveolar Proteinosis Cystic Fibrosis Mycobacterium Infections, Nontuberculous Cystic Fibrosis (CF) MRSA

Clinical Trials (10)

NCT06431776 Phase 3 RECRUITING

Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

Started: 10/22/2025

NCT04544293 Phase 3 ACTIVE NOT RECRUITING

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Started: 5/19/2021

NCT03482752 Phase 3 TERMINATED

Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis

Started: 4/16/2018

NCT03181932 Phase 3 COMPLETED

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

Started: 9/20/2017

NCT03421743 Phase 2 COMPLETED

Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection

Started: 3/1/2018

NCT02702180 Phase 2 COMPLETED

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis

Started: 3/21/2016

NCT03597347 Phase 2 TERMINATED

Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

Started: 6/20/2019

NCT01746095 Phase 2 COMPLETED

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

Started: 3/1/2013

NCT02468908 Phase 1 COMPLETED

Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects

Started: 5/1/2015

NCT01537666 Phase 1 COMPLETED

Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics

Started: 11/1/2011

Drug Candidates

Molgramostim Molgramostim Open-label Inhaled molgramostim Antimycobacterial regimen Molgramostim nebulizer solution Vancomycin inhalation powder Vancomycin hydrochloride inhalation powder AeroVanc IV vancomycin hydrochloride
Activity Status: Slowing
Last Trial Started: 10/22/2025
Last Trial Ended: 1/15/2021
Trials (12 months): 0
Completed Trials: 6
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.